Spinal Cord Injury Research Program Clinical Trial Award
ID: 353184Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRAA), is offering the Fiscal Year 2024 Spinal Cord Injury Research Program Clinical Trial Award to support innovative clinical trials aimed at improving treatments for traumatic spinal cord injury (SCI). Applicants are encouraged to propose research that addresses one or more of the identified focus areas, such as spinal cord tissue protection, biomarker validation, and psychosocial issues, with an emphasis on community engagement and collaboration among military, academic, and community institutions. The program has an estimated total funding of $14.56 million, with awards potentially reaching up to $3 million in direct costs, and key deadlines include a pre-application due by May 20, 2024, followed by a full application submission by August 30, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Defense (DOD) is announcing the Fiscal Year 2024 (FY24) Spinal Cord Injury Clinical Trial Award under the Congressionally Directed Medical Research Programs. This program supports research aimed at improving treatments for traumatic spinal cord injury (SCI), with $40 million available for grants. Proposals must address at least one of the identified focus areas, including spinal cord tissue protection at injury time, biomarker validation, psychosocial issues in SCI patients, and effective intervention development for various health complications. The submission process for applicants is two-fold: a pre-application due by May 20, 2024, followed by an invitation for full application submission by August 30, 2024. The SCIRP seeks to leverage partnerships between military, community, and academic institutions to enhance research validity and relevance. Awards may provide up to $3 million in direct costs, with emphasis on community engagement through collaborative research strategies. The application must showcase a comprehensive understanding of clinical trial protocols and the anticipated impact on military service members, veterans, and the broader SCI community, ensuring the proposed studies align with program objectives and regulatory compliance.
    Similar Opportunities
    DOD Duchenne Muscular Dystrophy, Clinical/Translational Research Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a grant opportunity for the Duchenne Muscular Dystrophy Research Program's Clinical/Translational Research Award (CTRA) for fiscal year 2025. This funding initiative aims to support advanced translational research that accelerates promising ideas in Duchenne muscular dystrophy (DMD) into clinical applications, particularly focusing on therapies effective across all age groups, including infants and nonambulatory individuals. With an estimated total program funding of approximately $8.56 million, the program anticipates awarding around five grants, encouraging collaborations with early-career investigators and requiring applications to include preliminary data relevant to DMD. Interested applicants should note that a pre-application is due by July 25, 2025, with full applications due by August 8, 2025; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DOD Amyotrophic Lateral Sclerosis, Pilot Clinical Trial Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY25 Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award to support clinical trials aimed at improving the treatment and management of Amyotrophic Lateral Sclerosis (ALS). Applicants are required to focus on either biomarker-driven interventions or enhancements in clinical care, with an emphasis on incorporating community collaboration to optimize research impact. This funding opportunity allocates approximately $6.6 million to support around two pilot clinical trial applications, with a direct cost cap of $2 million for each project. Interested parties must submit a pre-application by June 6, 2025, followed by a full application due on August 27, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    DoD Military Burn, Patient-Centered Research Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY25 Military Burn Research Program's Patient-Centered Research Award (PCRA) to enhance clinical practices and interventions for burn victims in combat conditions. This grant opportunity, with an estimated total funding of $3.4 million, specifically supports clinical research involving human subjects, excluding preclinical studies, and aims to bridge the gap between research and practical application in austere environments. Proposals should focus on improving acute burn care practices, developing methods to prevent and treat cold injuries, and managing complications such as fluid resuscitation and inhalation injuries, with a strong emphasis on military health relevance and potential impact. Interested applicants must submit pre-applications by June 23, 2025, and full applications by September 8, 2025, with funding announcements expected by September 30, 2026. For further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DOD Amyotrophic Lateral Sclerosis, Clinical Outcomes and Biomarkers Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is inviting applications for the Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) for fiscal year 2025. This grant aims to support the development and validation of clinical outcomes and biomarkers specifically for enhancing clinical trials in Amyotrophic Lateral Sclerosis (ALS), focusing on targeted therapies or genetic mutations rather than broad applicability to all patients. With an estimated total program funding of $6.2 million, the program anticipates awarding approximately five grants, each with a maximum budget of $750,000 for a duration of up to three years. Interested applicants must submit a pre-application by June 6, 2025, followed by a full application due by August 27, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Alzheimer’s Research Program Transforming Care Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Alzheimer's Research Program Transforming Care Award to support innovative clinical research aimed at improving care for individuals with Alzheimer's disease and related dementias (AD/ADRD). This funding opportunity encourages community collaboration and requires projects to focus on interventions that enhance the quality of life for both patients and their caregivers. Approximately $5.2 million is available to fund around three awards, with pre-applications due by June 12, 2025, and full applications due by August 29, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    DOD Amyotrophic Lateral Sclerosis, Therapeutic Idea Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Therapeutic Idea Award (TIA) under the fiscal year 2025 Amyotrophic Lateral Sclerosis Research Program (ALSRP). This grant aims to support innovative, high-risk research proposals focused on drug or therapy development for Amyotrophic Lateral Sclerosis (ALS), with an emphasis on generating preliminary data for future therapeutic investigations. The program has a total funding amount of approximately $10.8 million, with individual awards capped at $600,000 and a performance period not exceeding two years. Interested applicants must submit pre-applications by June 6, 2025, and full applications by August 27, 2025; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Disability and Rehabilitation Research Projects (DRRP) Program: Research on Non-Traumatic Spinal Cord Injury
    Administration for Community Living
    The Administration for Community Living is forecasting a grant opportunity under the Disability and Rehabilitation Research Projects (DRRP) Program, focusing on research related to non-traumatic spinal cord injury. The objective of this grant is to enhance the effectiveness of services authorized under the Rehabilitation Act by generating new knowledge and developing methods and technologies that improve outcomes for individuals with disabilities, particularly those with significant support needs. This initiative is crucial for advancing rehabilitation practices and understanding the experiences of affected individuals. The grant has an estimated total funding of $500,000, with a project period of 60 months, and interested applicants can reach out to Brian Bard at 202-795-7298 or via email at Brian.Bard@acl.hhs.gov for further details. Key deadlines include an estimated synopsis post date of February 11, 2025, and a close date of April 11, 2025.
    DOD Amyotrophic Lateral Sclerosis, Therapeutic Development Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) to support innovative research aimed at developing therapies for Amyotrophic Lateral Sclerosis (ALS). This grant program seeks applications that demonstrate proof-of-concept efficacy in preclinical models of ALS, with a focus on empirical therapeutic studies and the development of mechanism-specific biomarkers to enhance trial design and patient selection. With an estimated total funding of approximately $9.8 million, the program anticipates awarding about four grants, each capped at $1.5 million for a maximum duration of three years. Interested applicants must submit a pre-application by June 6, 2025, followed by a full application due by August 27, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Alzheimer’s Research Program Transforming Research Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Alzheimer's Research Program Transforming Research Award to support innovative research aimed at reducing the risk of Alzheimer's disease and related dementias (AD/ADRD). This grant opportunity encourages diverse applicants, including for-profit, non-profit, and academic institutions, and emphasizes the necessity of community collaboration, particularly for clinical research projects. With an estimated total program funding of $4 million, the program anticipates awarding approximately four grants, each providing up to $1 million over a maximum of three years. Interested applicants must submit a pre-application by June 12, 2025, followed by a full application due by August 29, 2025. For further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DOD Duchenne Muscular Dystrophy, Idea Development Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research Acquisition Activity (USAMRAA), is offering the Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) for fiscal year 2025. This grant aims to support innovative, high-risk research that seeks to improve outcomes for individuals with Duchenne muscular dystrophy (DMD), encouraging applications that present well-formulated hypotheses based on solid scientific rationale. The program is particularly focused on studies targeting the primary pathology of DMD and emphasizes collaboration among experienced researchers, while excluding clinical trials in favor of fundamental and preparatory research. The total funding available is approximately $1.68 million, with up to three awards capped at $350,000 each for direct costs over a maximum of two years. Interested applicants must submit a pre-application by July 2025, followed by a full application by August 2025, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.